
Nexviazyme®
(avalglucosidase alfa)
Six Minute Walk Test (6MWT)
Help improve their mobility - move to Nexviazyme1
Patients treated with NEXVIAZYME walked 30 metres further in the 6MWT vs patients treated with MYOZYME (alglucosidase alfa) at Week 49 (nominal P=0.04).‡1

‡Mixed model for repeated measures was used to test primary and secondary endpoints. As superiority was not established for FVC% predicted (P=0.06), formal testing was stopped as per the protocol hierarchy; P-values generated for secondary endpoints are at nominal level without multiplicity adjustment.
*Mean (SD) pre-treatment baseline 6MWT distances were 399.3 m (110.9 m) and 378.1 m (116.2 m) for the Nexviazyme and Myozyme treatment groups, respectively.1
†LS mean; without multiplicity adjustment.1
6MWT, 6 minute walk test; CI, confidence interval; LS, least squares; SD, standard deviation; SE, standard error.
- Nexviazyme Australian Approved Product Information.
PBS Information: NEXVIAZYME. This product is not listed on the PBS. This product is funded under the Life Saving Drugs Program.
Please review full Nexviazyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.
â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
PBS Information: MYOZYME. This product is not listed on the PBS. This product is funded under the Life Saving Drugs Program.
Please review full Myozyme Product Information before prescribing. Full Product Information is available from sanofi-aventis australia pty ltd here or by contacting 1800 818 806.
Life Saving Drugs Program - Pompe disease - Guidelines are available at www.health.gov.au/resources/publications/lsdp-pompe-guidelines.
Nexviazyme® and Myozyme​​​​​​​® are registered trademarks of Sanofi.
MAT-AU-2201156 - 2.0 - 05/2024